298 related articles for article (PubMed ID: 33555117)
21. Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel
Shimizu N; Akashi Y; Fujii T; Shiono H; Yane K; Kitahara T; Ohta Y; Kakudo K; Wakasa T
Anticancer Res; 2019 Jan; 39(1):413-420. PubMed ID: 30591488
[TBL] [Abstract][Full Text] [Related]
22. Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
Bronte G; Delmonte A; Burgio MA; Verlicchi A; Puccetti M; Bravaccini S; Cravero P; Tumedei MM; Diano D; Rossi G; Ulivi P; Martinelli G; Crinò L
Lung Cancer; 2020 Apr; 142():47-50. PubMed ID: 32088605
[TBL] [Abstract][Full Text] [Related]
23. Reticular Myxoid Odontogenic Neoplasm with Novel STRN::ALK Fusion: Report of 2 Cases in 3-Year-Old Males.
Rosebush MS; Smith MH; Cordell KG; Callahan N; Zaid W; Gagan J; Bishop JA
Head Neck Pathol; 2024 Mar; 18(1):26. PubMed ID: 38526831
[TBL] [Abstract][Full Text] [Related]
24. Integrative analysis of oncogenic fusion genes and their functional impact in colorectal cancer.
Choi Y; Kwon CH; Lee SJ; Park J; Shin JY; Park DY
Br J Cancer; 2018 Jul; 119(2):230-240. PubMed ID: 29955133
[TBL] [Abstract][Full Text] [Related]
25. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
[TBL] [Abstract][Full Text] [Related]
26. Detection of Anaplastic Lymphoma Kinase-Rearranged Mesothelioma Cells in Ascites by Companion Diagnostics.
Konishi M; Kanyama T; Maeno K; Miyagawa C; Minamiguchi S; Katsushima H; Shimada T
Acta Cytol; 2020; 64(4):378-385. PubMed ID: 31661685
[TBL] [Abstract][Full Text] [Related]
27. A Rare
Yang Y; Qin SK; Zhu J; Wang R; Li YM; Xie ZY; Wu Q
Mayo Clin Proc Innov Qual Outcomes; 2017 Jul; 1(1):111-116. PubMed ID: 30225407
[TBL] [Abstract][Full Text] [Related]
28.
Bastos AU; de Jesus AC; Cerutti JM
Eur J Endocrinol; 2018 Jan; 178(1):83-91. PubMed ID: 29046324
[TBL] [Abstract][Full Text] [Related]
29. Clinical Utility of Cell-Free DNA for the Detection of
McCoach CE; Blakely CM; Banks KC; Levy B; Chue BM; Raymond VM; Le AT; Lee CE; Diaz J; Waqar SN; Purcell WT; Aisner DL; Davies KD; Lanman RB; Shaw AT; Doebele RC
Clin Cancer Res; 2018 Jun; 24(12):2758-2770. PubMed ID: 29599410
[No Abstract] [Full Text] [Related]
30. Malignant pleural mesothelioma with an EML4-ALK fusion: Expect the unexpected!
Cordier F; Van der Meulen J; van Roy N; De Wilde J; van Dijck H; Vanhoenacker F; Lambrechts M; Noyez V; Van de Vijver K; Ferdinande L; Dendooven A; Van Dorpe J; Creytens D
Pathol Res Pract; 2022 Mar; 231():153772. PubMed ID: 35074700
[TBL] [Abstract][Full Text] [Related]
31. A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK.
Penzel R; Schirmacher P; Warth A
J Thorac Oncol; 2012 Jul; 7(7):1198-9. PubMed ID: 22706607
[TBL] [Abstract][Full Text] [Related]
32. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.
van der Krogt JA; Bempt MV; Ferreiro JF; Mentens N; Jacobs K; Pluys U; Doms K; Geerdens E; Uyttebroeck A; Pierre P; Michaux L; Devos T; Vandenberghe P; Tousseyn T; Cools J; Wlodarska I
Haematologica; 2017 Sep; 102(9):1605-1616. PubMed ID: 28659337
[TBL] [Abstract][Full Text] [Related]
33. Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review.
Wu X; Wang Q; Xu X
Front Oncol; 2023; 13():1156329. PubMed ID: 37152028
[TBL] [Abstract][Full Text] [Related]
34. Salivary Secretory Carcinoma Harboring a Novel ALK Fusion: Expanding the Molecular Characterization of Carcinomas Beyond the ETV6 Gene.
Sasaki E; Masago K; Fujita S; Suzuki H; Hanai N; Hosoda W
Am J Surg Pathol; 2020 Jul; 44(7):962-969. PubMed ID: 32205481
[TBL] [Abstract][Full Text] [Related]
35. Identification of novel ALK rearrangements in gynecologic clear cell carcinoma.
Yang C; Zhang L; Love-Gregory L; Sun L; Hagemann IS; Cao D
Int J Cancer; 2021 Jan; 148(2):459-468. PubMed ID: 33034056
[TBL] [Abstract][Full Text] [Related]
36. Detection of an
Lai AZ; Schrock AB; Erlich RL; Ross JS; Miller VA; Yakirevich E; Ali SM; Braiteh F
Oncologist; 2017 Jul; 22(7):774-779. PubMed ID: 28507204
[TBL] [Abstract][Full Text] [Related]
37. Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report.
Zhu L; Ma S; Xia B
Front Oncol; 2022; 12():1009076. PubMed ID: 36439495
[TBL] [Abstract][Full Text] [Related]
38. Investigation of the Relationship Between Radiation Dose and Gene Mutations and Fusions in Post-Chernobyl Thyroid Cancer.
Efanov AA; Brenner AV; Bogdanova TI; Kelly LM; Liu P; Little MP; Wald AI; Hatch M; Zurnadzy LY; Nikiforova MN; Drozdovitch V; Leeman-Neill R; Mabuchi K; Tronko MD; Chanock SJ; Nikiforov YE
J Natl Cancer Inst; 2018 Apr; 110(4):371-378. PubMed ID: 29165687
[TBL] [Abstract][Full Text] [Related]
39.
Kelly AD; Wiklund T; Kononen J; Creeden J
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34423228
[No Abstract] [Full Text] [Related]
40. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
